Pacira BioSciences (PCRX) investor relations material

Strategic priorities and outlook

• Focused on non-opioid pain management with three marketed products and a growing pipeline.

• Implemented a 'five by 30' strategy targeting 3 million patients, double-digit CAGR, and margin expansion by 2030.

• Achieved strong Q1 results: EXPAREL sales up 5%, ZILRETTA up 15%, iovera up 21% year-over-year.

• Anticipates convergence of volume and sales growth as GPO effects normalize.

• Emphasizes expanding access and coverage, especially outside bundled reimbursement.

Growth drivers and market access

• NOPAIN Act, effective January 2025, is expected to drive significant volume growth among Medicare patients.

• Expansion in covered lives outside the bundle is a key focus, with 110 million currently covered.

• Ex-U.S. growth through LG Chem partnership in Asia-Pacific and ongoing international agreements.

• Additional growth expected from future price increases and broader payer adoption.

• Direct negotiations with major payers aim to further expand commercial access.

Intellectual property and exclusivity

• Strengthened patent portfolio for EXPAREL, now with 21 Orange Book-listed patents.

• Favorable settlement delays generic entry until 2030, with gradual entry until unlimited access in 2039.

• Ongoing legal proceedings for other ANDA filings expected to last through 2030.

• Continued innovation and new patent filings planned for the next two years.

• Diversification of portfolio and pipeline to mitigate future generic competition.